1680P - Molecular profiling of high-risk localized prostate cancer (HRLPC) treated with docetaxel (D) and complete androgen blockade (CAB) prior to radical...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anticancer agents
Prostate Cancer
Biological therapy
Presenter Mercedes Marín-Aguilera
Authors M. Marín-Aguilera1, A. Font2, E. Gallardo3, A. Alcaraz4, V. Pereira5, M.J. Ribal4, J. Areal6, N. Hannaoui7, P. Gascon8, B. Mellado5
  • 1Translational Oncology Laboratory, Fundacio Clínic per a la Recerca Biomèdica, 08036 - Barcelona/ES
  • 2Medical Oncology, Institut Català d'Oncologia-Badalona, 08916 - Badalona/ES
  • 3Oncologia Medica, Hospital de Sabadell Corporacis Parc Tauli, ES-08208 - Sabadell/ES
  • 4Urology, Hospital Clínic, 08036 - Barcelona/ES
  • 5Medica Oncology, Hospital Clínic, 08036 - Barcelona/ES
  • 6Urology, Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 7Urology, Hospital Parc Tauli, 08208 - Sabadell/ES
  • 8Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES



HRLPC has an increased risk of positive margins and recurrence after local treatment. Neoadjuvant docetaxel has not shown to increase the percentage of pathological complete responses (pRCs) respect to hormone-therapy alone. In a previous phase II trial of neoadjuvant D plus CAB in patients with HRLPC we reported a 6% pRCs. (Mellado B, Br J Cancer 2009). We proposed that the molecular analysis of residual tumor cells after D + CAB may help to identify molecular mechanisms of treatment resistance.


93 genes potentially involved in D resistance were selected from a previous molecular study of our group (Marin-Aguilera M, Mol Cancer Ther 2012). Gene transcriptional levels were analyzed by using Taqman low density arrays in 28 formalin-fixed paraffin-embedded (FFPE) tumors from HRLPC patients treated with D + CAG prior radical prostatectomy, and in 36 HRLPC patients who underwent radical prostatectomy without neoadjuvant therapy. GUSB housekeeping gene was the reference for normalization. Gene expression determination was performed with RQ Manager Software for manual data analysis.


Differential gene expression of 67.7% (63 of 93 analyzed genes) was found in neoadjuvant treated tumors versus samples without neoadjuvant treatment (P < 0.05). Among them, there were found differences in the expression of genes related with androgen receptor signalling, NFkB transcription factor and epithelial-mesenquimal transition processes. Data on gene expression and its correlation with clinical outcome will be presented at the meeting.


Residual tumor cells in prostatectomy specimens after neoadjuvant hormone- and chemotherapy treatment already exhibits a gene expression profile that may be involved in hormone/chemo resistant phenotype.


All authors have declared no conflicts of interest.